A Phase 1a/1b Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers

Trial Profile

A Phase 1a/1b Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Cabiralizumab (Primary) ; Nivolumab
  • Indications Colorectal cancer; Glioblastoma; Glioma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Five Prime Therapeutics
  • Most Recent Events

    • 09 Nov 2017 According to a Bristol-Myers Squibb media release, this trial has started to enroll and treat an additional 30 pancreatic cancer patients to evaluate the combination in a total of 60 patients.
    • 09 Nov 2017 According to a Bristol-Myers Squibb media release, as of data cut-off, 229 patients have been treated, 205 patients in the combination dose expansion cohorts in advanced solid tumours and 33 pancreatic cancer patients.
    • 09 Nov 2017 Results published in the Bristol-Myers Squibb Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top